DMHA (Octodrine)
STIMULANTAlso known as: 2-Aminoisoheptane, Octodrine, 2-amino-6-methylheptane, 1,5-Dimethylhexylamine
What is DMHA (Octodrine)?
DMHA (2-aminoisoheptane) is a synthetic stimulant originally developed in the 1950s as an inhaled nasal decongestant—never approved for oral use. It emerged as a DMAA alternative in pre-workout supplements after the 2013 DMAA ban.
Why is DMHA (Octodrine) Banned?
FDA determined DMHA is an unsafe food additive. Never tested for oral human use at supplement doses. Products are adulterated under DSHEA.
Health Risks & Side Effects
Health Risk Level
This substance has a high risk of overdose and moderate addiction potential.
warningCommon Side Effects
- arrow_rightHypertension
- arrow_rightTachycardia
- arrow_rightHyperthermia
- arrow_rightAnxiety
- arrow_rightJitters
- arrow_rightInsomnia
blockContraindications
- arrow_rightHeart conditions
- arrow_rightHigh blood pressure
- arrow_rightAnxiety disorders
- arrow_rightStimulant sensitivity
How Does DMHA (Octodrine) Work?
Sympathomimetic amine that stimulates norepinephrine release, causing increased heart rate, blood pressure, and thermogenesis.
History
Originally patented in the 1950s as a nasal decongestant. Resurfaced in supplements around 2016 as 'DMAA alternative'. FDA cracked down in 2019 with 12 warning letters to companies including Hi-Tech Pharmaceuticals.
verified_userSafe Legal Alternatives
Don't risk your health with DMHA (Octodrine). Here are proven, legal alternatives that provide similar benefits safely:
No alternatives available at this time. Check back soon.
Learn More
Research articles and educational resources
Overview
Octodrine
Octodrine, also known as dimethylhexylamine (DMHA) and sold under the brand name Vaporpac among others, is a sympathomimetic and stimulant medication that was formerly used in the treatment of hypotension.
Scientific Research
From PubMed • 1 peer-reviewed study
Four experimental stimulants found in sports and weight loss supplements: 2-amino-6-methylheptane (octodrine), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylamylamine (1,3-DMAA) and 1,3-dimethylbutylamine (1,3-DMBA).
The United States Food and Drug Administration banned the stimulant 1,3-dimethylamylamine (1,3-DMAA) from dietary supplements and warned consumers that the stimulant can pose cardiovascular risks ranging from high blood pressure to heart attacks.